EC approves GSK's Tafinlar

The European Commission approved an MAA from GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) for Tafinlar dabrafenib as monotherapy to treat adults with unresectable or metastatic melanoma with a BRAF V600 mutation. The oral BRAF protein kinase inhibitor is also approved in the U.S. as monotherapy to treat melanoma with BRAF V600E mutations as detected by an FDA-approved test. ...